Treatment Interruption for HIV
(SCOPE-ATI Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy within three weeks, even if the virus does not rebound during this time.
Do I have to stop taking my current medications for the trial?
Yes, you will need to pause your HIV medications (antiretroviral therapy) for this trial. The study involves interrupting these medications to understand their interaction with the virus.
Is the treatment interruption for HIV using Raltegravir (Isentress) safe for humans?
How is the drug Raltegravir (Isentress) unique in treating HIV?
Raltegravir (Isentress) is unique because it is the first drug in a new class called integrase inhibitors, which target a different part of the HIV virus compared to other treatments. It is effective for patients with drug-resistant HIV and can be used in both treatment-experienced and treatment-naive patients, offering flexibility in administration without food restrictions.12367
What data supports the effectiveness of the drug Raltegravir (Isentress) for HIV treatment?
Who Is on the Research Team?
Steven J Deeks, MD
Principal Investigator
University of California, San Francisco
Are You a Good Fit for This Trial?
This trial is for adults over 18 with HIV who've been on antiretroviral therapy (ART) for at least a year, have undetectable virus levels, and a CD4+ count above 350. They must use two contraception methods if they can have children and agree to counseling to prevent HIV spread. It's not for those with severe kidney or liver disease, active hepatitis B or C, recent cancer, heart issues, or using certain other drugs.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Interruption
Participants interrupt their antiretroviral therapy (ART) and undergo intensive sampling two to three times per week
Extended Treatment Interruption
Controllers may participate in an extended treatment interruption with less restrictive ART restart criteria
Follow-up
Participants are monitored for safety and effectiveness after treatment interruption
What Are the Treatments Tested in This Trial?
Interventions
- Treatment Interruption Arm
Treatment Interruption Arm is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor
Chan Zuckerberg Biohub
Collaborator